Focal transplantation–based astrocyte replacement is neuroprotective in a model of motor neuron disease
Open Access
- 19 October 2008
- journal article
- research article
- Published by Springer Nature in Nature Neuroscience
- Vol. 11 (11), 1294-1301
- https://doi.org/10.1038/nn.2210
Abstract
Recent work has suggested a role for astrocyte dysfunction in the etiology of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase (SOD1). Lepore et al. show here that transplantation of astrocyte-restricted progenitors in fact improves survival of rats expressing a human ALS-associated SOD1 allele. The rescue effect required the astrocytic glutamate transporter GLT1. Cellular abnormalities in amyotrophic lateral sclerosis (ALS) are not limited to motor neurons. Astrocyte dysfunction also occurs in human ALS and transgenic rodents expressing mutant human SOD1 protein (SOD1G93A). Here we investigated focal enrichment of normal astrocytes using transplantation of lineage-restricted astrocyte precursors, called glial-restricted precursors (GRPs). We transplanted GRPs around cervical spinal cord respiratory motor neuron pools, the principal cells whose dysfunction precipitates death in ALS. GRPs survived in diseased tissue, differentiated efficiently into astrocytes and reduced microgliosis in the cervical spinal cords of SOD1G93A rats. GRPs also extended survival and disease duration, attenuated motor neuron loss and slowed declines in forelimb motor and respiratory physiological functions. Neuroprotection was mediated in part by the primary astrocyte glutamate transporter GLT1. These findings indicate the feasibility and efficacy of transplantation-based astrocyte replacement and show that targeted multisegmental cell delivery to the cervical spinal cord is a promising therapeutic strategy for slowing focal motor neuron loss associated with ALS.Keywords
This publication has 49 references indexed in Scilit:
- GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALSPLOS ONE, 2007
- Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)Proceedings of the National Academy of Sciences, 2002
- Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor ImpairmentJournal of Neuroscience, 2001
- ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing InclusionsNeuron, 1997
- Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patientsNature Medicine, 1996
- Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) Using a Polymer Encapsulated Xenogenic Cell Line Engineered to Secrete hCNTF. Lausanne University Medical School, Lausanne, SwitzerlandHuman Gene Therapy, 1996
- Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of GlutamateNeuron, 1996
- Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosisAnnals of Neurology, 1995
- An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondriaNeuron, 1995
- Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase MutationScience, 1994